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Background: Tobacco use is the single most preventable cause of death, incurring huge resource costs in terms of
treating morbidity and lost productivity. This paper estimates smoking attributable mortality (SAM) as health costs
in 2014 in Israel.
Methods: Longitudinal data on prevalence of smokers and ex-smokers were combined with diagnostic and gender
specific data on Relative Risks (RR) to gender and disease specific population attributable risks (PAR). PAR was then
applied to mortality and hospitalization data from 2011, adjusted by population growth to 2014 to calculate SAM
and hospitalization days (SAHD) caused by active smoking. These were used as a base for calculating deaths,
hospital days and costs attributable to passive smoking, smoking by pregnant women, residential fires and
productivity losses based on international literature.
Results: The lagged model estimated active SAM in Israel in 2014 to be 7,025 deaths. Cardio-vascular causes
accounted for 45.0% of SAM, malignant neoplasms (39.2%) and respiratory diseases (15.5%). Lung cancer alone
accounted for 24.1% of SAM. There were an estimated 793, 17 and 12 deaths from passive smoking, mothers-to-be
smoking and residential fires. Total SAM is around 7,847 deaths (95% CI 7,698-7,997) in 2014.
We estimated 319,231 active SAHD days (95% CI 313,135-325,326). Respiratory care accounted for around one-half
of active SAHD (50.5%). Cardio-Vascular causes for 33.5% and malignant neoplasms (13.2%). Lung cancer only for
4.6%. Total SAHD was around 356,601 days including 36,049 days from passive smoking. Estimated direct acute care
costs of 356,601 days in a general hospital amount to around 849 (95% CI 832–865) million NIS ($244 million). Non
acute care costs amount to an additional 830 million NIS ($238 million). The total health service costs amount to
1,678 million NIS (95% CI 1,646-1,710) or $482 million, 0.2% of GNP. Productivity losses account for a further 1,909
million NIS ($548 million), giving an overall smoking related cost of 3,587 million NIS (95% CI 3,519-3,656) or $1,030
million, 0.41% of GNP).
Conclusions: Smoking causes a considerable burden in Israel, both in terms of the expected 7,847 lives lost and
the financial costs of around 3.6 million NIS ($1,030 million or 0.42% of GNP).
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Tobacco use is the single most preventable cause of death
[1], associated with more than five million deaths annually
worldwide [2]. By 2030, tobacco related mortality is likely
to rise to more than 8 million people [2]. Up to half of the
world’s more than one billion smokers will die prema-
turely of a tobacco-related disease [2]. Therefore, reducing* Correspondence: gary.ginsberg@moh.health.gov.il
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article, unless otherwise stated.the burden of disease from smoking is obviously of para-
mount importance in the field of public health.
In Israel, 2014 mid-year population 8,227,200 [3],
smoking prevalence among Jews has declined over the
period 1980-1997-2010 from 45.0%-32.4%-23.9% among
males and from 30.9%-25.0%-16.0% among females [4].
Amongst the non-Jewish population the decline has been
far less over the period 1997–2010 from 46.9% to 43.4%
among males, with a slight rise from 5.5% to 6.5% among
females.entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Ginsberg and Geva Israel Journal of Health Policy Research 2014, 3:28 Page 2 of 9
http://www.ijhpr.org/content/3/1/28In Israel, the first estimate of smoking attributable
mortality (SAM) was made for the 2001 National Gillon
Commission to decrease damage from smoking [5]. This
estimated 9,527 deaths from active smoking in 1999 and
a further 1,385 deaths from passive or enforced smoking
by foetuses, children, spouses and workmates. These es-
timates assumed a nine year lag period for each diagno-
sis, ignored elevated risks in ex-smokers and did not use
age-specific risk categories.
An improved SAM estimate of 8,664 deaths attribut-
able to active smoking in 2003 was published [6], based
on the expansion of categories in the US Centres for
Disease Control [7] on-line user-friendly computa-
tional program, called SAMMEC (Smoking Attribut-
able Mortality, Morbidity, and Economic Costs). This
estimate was based on
a) SAMMECs diagnosis list [7] which in turn was
based on the 2004 US Surgeon General’s Report [8].
b) The enormous body of US and international
literature on health risks due to tobacco use, which
includes major studies [9] and compendiums of
studies [10]. This was in order to correct for omitted
diagnoses in the SAMMEC list such as diabetes
which had subsequently been proven to be
smoking-related [11].
More importantly, the estimates corrected for the fact
that the standard SAMMEC approach did not consider
the latency period that occurs between exposure to the
risk factor (tobacco) and tobacco-induced mortality. The
estimates also expanded age categories to include per-
sons under 35 years old (who were excluded from the
SAMMEC estimates).
In 2007, SAM from active smoking was estimated to
be 8,932 deaths [5] using similar methodology to the
2003 estimates [6].
At the request of the ministry’s public health depart-
ment, we were asked to prepare estimates of mortality and
monetary costs attributable to smoking in 2014 in Israel
for inclusion into the minister’s report to parliament on
smoking in Israel, which was published in May 2014 [4].
Methods
Historical prevalence data on smokers was based on data
bases of the Ministry of Health’s health promotion de-
partment, National Health Surveys carried out by the
Central Bureau of Statistics (1996–7 and 1999), bi-
annual national telephone surveys (starting in 1994, the
latest one for 2013 being based on 6,014 respondents)
and National Health Surveys carried out by the Israeli
Center for Disease Control (2003–4 and 2007–2010) [4].
The basic methodology, including updated prevalence
surveys for current and ex-smokers by age and gender[4], mortality rates and relative risk (RR) estimates is de-
scribed in detail an earlier paper [6]. Smoking prevalence
data for 2014 was estimated by applying the relative de-
crease in gender and religion specific prevalence rates
from 2012 to 2013 to the period 2013 to 2014. These in-
cluded not only persons who reported smoking ciga-
rettes but also those who reported using other tobacco
products (like the hookah).
All calculations were based on an estimated mid-year
population in 2014 of 8,227,200 persons [3]. Cost were
at 2014 price levels using an average exchange rate for
the first half of 2014 of 3.481 NIS to the US dollar [14].
The surgeon general’s report of 2014 [13] was used to
provide the widely acceptable rubric of disease categories
providing up to date estimates of RR. Since it contained
many highly aggregated categories (other cancers, other
heart diseases, other vascular diseases), we dis-aggregated
the categories using values in the SAMMEC categorization
[7]. Meta-analyses of studies were used to provide RRs for
peptic ulcers [14-16], Crohn’s disease [17-21] and ulcerative
colitis in former smokers [17-19,21-23]. To complete the
list of diagnoses (Table 1), we added the specific (protective
effects) of Parkinson’s disease [24-26], endometrial cancer
[27-29] and ulcerative colitis in current smokers [17-23].
Calculation of SAM due to active smoking
We assumed persons who died younger had shorter lag-
times (between the act of smoking and SAM) than persons
who died at an older age [6]. Estimates of the lag-time
where made by subtracting the disease and gender-specific
average age at death by the gender-specific average age of
smokers.
We assumed a lag time for all diagnoses of 2.5, 5, 7.5
and 10 years for persons aged 20–24, 25–29, 30–34 and
for, 35–39-year-olds, reflecting the fact that the lengthy
lag-times for active smoking (e.g. 25–40 years) are non-
feasible in young persons.
A disease-specific age-related linear factor was applied to
the 40–54-year age group (i.e. with lower than average
time-lag). The average disease-specific lag-time was as-
sumed to occur in the 55–59-year-age group. The average
lag time estimates that we used varied from 23.7 years from
brain cancer to 40.4 years for coronary artery disease.
A disease specific age-related linear factor was also ap-
plied to the over 60 age group (i.e. with increasing above
average lag-time) within the constraints of achieving the
overall average disease and gender-specific time lag.
Next, for each diagnostic, age and gender group, smok-
ing prevalence was obtained for the year relating to 2014
less the lag-time.
Data on RR was combined with lagged smoking preva-
lence data based on the following formula applied to
each diagnosis, age and gender category and finally ag-
gregated [7]:
Table 1 Relative risk (RR) of SAM by smoking status, diagnosis and gender
Refs. Males RR current Females RR current
RR former RR former
Cancers:
[7] Bladder 3.27 2.09 2.22 1.89
[7] Cervical na Na 1.59 1.14
Endometrial na Na 0.74 0.88
[7] Esophageal 6.76 4.46 7.75 2.79
[7] Larengeal 14.60 6.34 13.02 5.16
[7] Leukemia 1.86 1.33 1.13 1.38
[13] Lung 22.25 6.06 21.15 5.75
[7] Lip, bucal, pharynx 10.89 3.40 5.08 2.29
[7] Pancreatic 2.31 1.15 2.25 1.55
[7] Renal 2.72 1.73 1.29 1.05
[7] Stomach 1.96 1.47 1.36 1.32
[13,30] Unspecified 2.31 1.41 1.83 1.26
[13,30] Other cancers (a) 4.16 1.83 1.06 1.01
Respiratory:
[13] Tuberculosis 3.49 1.92 2.51 2.32
[13] Bronchitis 19.66 5.67 19.67 7.55
[13] COPD inc emphysema 21.08 5.97 19.09 8.05
[13] Pneumonia 3.99 1.96 2.21 1.68
[13,31] Asthma adults 1.99 1.26 2.18 1.48
[13,30,32] Other respiratory (b) 1.94 1.25 3.09 2.17
Vascular:
[13] Rheumatic heart disease 2.17 1.17 2.01 1.18
[7] Aortic aneurism 6.21 3.07 7.07 2.07
[13] Coronary artery disease 2.87 1.55 3.03 1.49
[13] Coronary heart disease 2.71 1.51 3.01 1.49
[13,30] Cardiac dysrhythmias 4.29 1.93 4.29 1.66
[13,30] Myocardial infarction 2.01 1.31 8.84 3.44
[13,30] Peripheral vascular disease 7.73 3.03 7.73 3.09
[7,13,30] Other heart diseases (c) 2.17 1.25 2.02 1.19
Cerebrovascular disease
[13] Ages 35-64 2.47 1.35 2.15 1.35
[13] Ages 65+ 1.74 1.16 1.85 1.26
Digestive system:
[17-21] Crohn’s disease 1.70 1.22 1.70 1.22
[14-16] Peptic ulcers 2.00 1.28 2.36 1.39
[17-23] Ulcerative colitis 0.70 1.55 0.70 1.55
Endocrine-metabolic
[13] Diabetes 1.86 1.31 1.62 1.31
Other:
Parkinson’s disease 0.37 0.76 0.36 0.69
(a) includes breast, respiratory in situ, renal pelvis and vulvar
(b) includes cough, dsypnoea and other respiratory diseases
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Attributable Fraction (SAF)
where
SAF ¼ p0 þ p1 RR1ð Þ þ p2 RR2ð Þð Þ − 1½ =
p0 þ p1 RR1ð Þ þ p2 RR2ð Þ½ 
and
P0 = Percentage of never smokers
P1 = Percentage of current smokers
P2 = Percentage of former smokers
RR1 = Relative risk of death for current smokers
relative to never smokers
RR2 = Relative risk of death for former smokers
relative to never smokers
Calculation of SAM due to passive smoking and
residential fires
Deaths caused by passive smoking in Israel were esti-
mated by adjusting the US figure [13] of 9.44% of active
SAM by the relative differences in smoking prevalence
between the USA (males 16.7%, females 13.6%) [13,33]
and Israel (males 24.9%, females 12.6%) in 2010 [4,34].
In order to estimate foetal SAM in Israel, USA data
showing foetal SAM to be 0.232% of active SAM [13]
was adjusted
a) By the ratio of the Israeli National Smoking
prevalence in pregnant women of 6.82%, (as a result
of 46.5% of pregnant women stopping smoking) [34]
to the USA figure of 8.43% [35].
b) By Israel’s 30.6% higher birth rate [36,37] to give an
estimate that foetal SAM accounts for 0.244% of
active SAM in Israel.
Deaths caused by residential fires related to cigarette
causes was estimated by adjusting the US figure [13] of
0.14% of active SAM deaths by the relative differences
by the smoking prevalence between the USA and Israel
Cost of treating smoking-attributable morbidity
The initial morbidity cost estimates includes only of the
direct costs of acute care viewed from a “narrow” health
services perspective as there are no readily available data
in Israel on costs that fall outside the health system,
such as work absences, transportation to receive treat-
ment and out-of-pocket expenses.
Active Smoking Attributable hospitalization days (SAHD)
were calculated in a similar way to acute SAM estimates.
These were based on actual numbers of diagnosis specific
hospitalization utilization rates by age and gender from
2011, being applied to population data in 2014.
Hospitalization costs were calculated by summing:-a) The product of the estimated number of
hospitalization days in non-ICU units by the 2,251
New Israeli Shekels (NIS) per day tariff of the Ministry
of Health [38]
and
b) Based on ICU accounting for 4.6% of adult
non-obstetric general bed use [39], the product of ICU
hospitalization days and 5,046 NIS, being 224% times
the per-diem cost of non-ICU hospitalizations [39].
An approximation of the other non-acute direct costs
(such as for medications, ambulatory care, nursing home
care and rehabilitation) attributable to smoking was based
on applying the latest estimate from the USA [13] showing
that non-acute direct costs were 97.8% of smoking attrib-
utable acute care costs.
A further very rough approximation of “indirect costs”
in Israel was based on USA data [13] showing that lost
productivity costs alone, due to current and ex-smokers
having higher rates of absenteeism than never smokers,
to be 225% that of the costs of smoking attributable
acute hospital care [13]. This impact was “dose related”
in the sense that heavy smokers having higher levels of
absenteeism than lighter smokers [40].
Results
The updated lagged model estimated active SAM in Israel
in 2014 to be 7,025 deaths (95% CI 6,875-7,175), after taking
into account an estimated 174 and four fewer deaths, due to
the protective effects of smoking on Parkinson’s disease and
endometrial cancers respectively (Table 2). Cardio-vascular
causes accounted for 45.0% of SAM, malignant neoplasms
(39.2%) and respiratory diseases (15.5%). Six specific diagno-
ses alone accounted for over three-quarters of SAM:- Lung
Cancer (24.1%), Coronary Artery Disease (18.5%), COPD in-
cluding emphysema (13.0%), Myocardial Infarction (10.9%),
Cerebrovascular Disease (6.1%) and Coronary Heart Disease
(5.0%). Around 60.6% of SAM occurred in males.
Passive (or enforced smoking was estimated to account
for an additional 11.29% of active SAM in Israel, amounting
to estimated 793 further deaths. Exposure of the foetus to
mothers smoking accounted for an estimated 0.24% of ac-
tive SAM, or 17 additional foetal deaths. While residential
fire accounted for an estimated 0.17% of active SAM, or 12
additional deaths. Therefore total SAM will be around
7,847 deaths (95% CI 7,698-7,997) in 2014 or 16.8% of over-
all expected mortality.
The model estimated that there were 319,231 (95% CI
313,135-325,326) active SAHD days in Israel in 2014
(Table 3). Respiratory care accounted for around one-half
of active SAHD (50.5%). Cardio-Vascular causes accounted
for 33.5% and malignant neoplasms (13.2%). Lung cancer
accounted for only 4.6%. Around 63.0% of SAM occurred
in males.
Table 2 Active smoking attributable mortality-Israel 2014
Males Females Total
Cancers:
Bladder 155 27 182
Cervical 0 10 10
Endometrial 0 −4 −4
Esophageal 65 2 67
Larengeal 54 7 61
Leukemia 90 13 103
Lung 1127 562 1690
Lip, bucal, pharynx 29 11 39
Pancreatic 169 108 276
Renal 70 7 77
Stomach 109 23 132
Unspecified 43 23 67
Ureter 2 0 2
Other cancers 39 9 48
Respiratory:
Tuberculosis 3 0 3
Bronchitis 6 4 9
COPD inc emphysema 522 394 916
Pneumonia 10 2 13
Asthma adults 10 22 32
Other respiratory 55 58 114
Cardio-vascular:
Rheumatic heart disease 12 14 27
Aortic aneurism 60 30 90
Coronary artery disease 808 489 1297
Coronary heart disease 190 164 355
Cardiac dysrhythmias 36 23 59
Myocardial infarction 266 499 765
Peripheral vascular disease 54 77 132
Other heart disease 4 1 5
Cerebrovascular disease 230 200 430
Digestive system:
Crohn’s disease 1 1 2
Peptic ulcers 2 3 5
Ulcerative colitis −0.1 −0.1 −0.2
Endocrine-metabolic:
Diabetes 115 80 194
Other:
Parkinson’s disease −80 −94 −174
Total 4256 2769 7025
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from passive smoking. A further 780 days were attribut-
able to exposure of the foetus to mothers smoking and
541 due to residential fires caused by cigarettes. Therefore
total SAHD will be around 356,601 (95% CI 357,908-
371,915) days in 2014.
Estimated direct acute care costs of 356,601 days in a
general hospital amount to around 849 (95% CI 832–
865) million NIS ($244 million). An additional 830 mil-
lion NIS ($238 million) is estimated for out-of hospital
costs including ambulatory care, emergency room visits,
out- patient visits and rehabilitation. The total health ser-
vice costs are therefore 1,679 (95% CI 1,646-1,710) million
NIS ($482 million) representing 2.6% of the health budget
or 0.2% of GNP. Productivity losses account for a further
1,909 million NIS ($548 million, based on 225% that of
acute care costs of 849 million NIS) giving an overall
smoking related cost of 3,587 (95% CI 3,519-3,656) million
NIS ($1,030 million) or 0.41% of GNP.
Discussion
Smoking remains a huge preventable risk factor account-
ing for approx. 7,847 deaths in Israel (of which 7,025 are
from active smoking alone). Approximately one death in
every six is attributable to smoking. The monetary impact
on health service resources and society amounts to around
3,587 million ($1,030 million), around 0.41% of GNP.
While Hypertension was originally included in the
SAMMEC list [41,42], it has subsequently been dropped
and also does not appear in the Surgeon-Generals list.
However a recent longitudinal study of 5,512 Japanese
males [43] found smoking to be an independent risk fac-
tor for hypertension with an adjusted RR of 1.13 (95%
CI 1.03 – 1.23). Applying this risk factor to both genders
would add an additional 55 deaths to our acute SAM
(and additional 487 acute SAHD).
The decrease of active SAM from previous estimates
is partly a result of the secular downward trend in smok-
ing prevalence that has been continuing for the past
40 years, falling in males from 50.6% in 1974 to 36.2% in
1994 and 25.2% in 2013, and from 25.1% to 20.35 and
12.7% among females over the same period.
Another factor is decreases in the size of the RR of
diseases such as diabetes, heart and cerebrovascular dis-
ease as reported by the US surgeon-general [13]. These
however are partially offset by the reported increases in
RR of lung cancers [13]. While accounting for nearly a
quarter of all acute SAM, lung cancer only accounted
for 4.4% of acute SAHD, since chemotherapy and radio-
therapy are usually carried out on an out-patient basis,
with cancer patients being hospitalized for surgery and
hospice care.
The main limitation of the study is that we have made
the implicit assumption that the RR which we used were




Bladder 7,419 883 8,303
Cervical - 299 299
Endometrial - −308 −308
Esophageal 984 478 1,462
Laryngeal 1,519 298 1,817
Leukemia 2,154 300 2,454
Lung 9,392 5,156 14,548
Lip, bucal, pharynx 2,252 1,465 3,717
Pancreatic 1,530 1,059 2,589
Renal 2,206 166 2,372
Stomach 1,781 362 2,143
Unspecified 1,085 981 2,067
Other cancers 395 136 531
Respiratory:
Tuberculosis 281 37 318
Bronchitis 4,499 7,520 12,019
COPD incl. emphysema 29,141 17,857 46,997
Pneumonia 44,697 16,441 61,137
Asthma adults 616 1,511 2,126
Other respiratory 20,618 17,904 38,523
Cardio-vascular:
Rheumatic heart disease 522 664 1,186
Aortic aneurisms 3,071 553 3,624
Coronary artery disease 3,081 1,009 4,090
Coronary heart disease 3,064 1,084 4,148
Cardiac dysrhythmias 149 99 248
Myocardial infarction 12,306 13,369 25,676
Peripheral vascular disease 16,065 13,285 29,350
Other heart disease 3,975 908 4,883
Cerebrovascular disease 21,661 12,079 33,740
Digestive system:
Crohn’s disease 700 384 1,084
Peptic ulcers 114 87 200
Ulcerative colitis −16 −13 −29
Endocrine-metabolic:
Diabetes 7,272 3,103 10,375
Other:
Parkinson’s disease −1,586 −931 −2,517
Total hospital days 200,948 118,225 319,173
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would also apply to the Israeli population. Of course
there might be genetic or environmental factors that
would result in different disease specific RR based on an
Israeli population.
Secondly, the estimation of deaths and costs from pas-
sive, mothers smoking and residential fires is by necessity
based on US data. Each one of these categories deserves
separate calculations to be made based on Israeli specific
data. However, due to time limitations, we think it is better
to provide a guesstimate based on foreign data, than no
estimate at all.
The reader should therefore regard the quality of esti-
mates for active smoking as being good, but the esti-
mates for from passive, mothers smoking and residential
fires as being rough first-order estimates.
A recent national Israeli biomarker survey, indicated
widespread exposure to environmental tobacco smoke
(ETS) in the non-smoking Israeli adult population, espe-
cially among males, younger and less educated participants
[44]. However the data on urine cotinine concentrations,
based on a sample of only 248 persons, did not lend itself
to enable estimations of mortality losses due to ETS in
Israel. In addition, because good data on past ETS exposure
are not currently available in Israel, we only were able to
make a rough estimate of the harm due to second-hand
smoke exposure based on adapting US data [13].
The resultant rough estimate of 787 deaths due to pas-
sive smoking could be an under-estimate or over-estimate
as the potential relative exposure levels to passive smoking
were just based on one year’s smoking prevalence data, in-
stead of over a longer time period.
Also underestimated is the 12 deaths attributable to
residential fires (0.175% of active SAM) caused by ciga-
rettes since they do not include an estimate for non-
residential fires.
The estimate of non-hospital related direct costs can be
thought of as being conservative as it was based on being
97.8% of acute hospital costs [13]. This figure is lower than
previously published estimates of 102.1% in Hong-Kong
[45]. 102.5% in the USA [46], 107.5% in Germany [47],
113.2% in California [48] 135% in Taiwan [49], 161% in
China in 2000 [50] and 273% in China in 2008 [51].
It should be noted that there are health impacts of
smoking that do not have mortality consequences. The
cost of these are implicitly included in our calculations,
where we add 97.8% on to acute hospital costs for non-
acute hospital care (such as for infertility on an out-
patient basis).
For indirect costs, our estimate can again be thought
of as conservative as it only contained estimates of
smoking attributable lost productivity costs, thereby ex-
cluding transport costs, out-of-pocket expenditures and
premature burial costs.
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from obesity [52], lack of physical exercise [53], motor ve-
hicle emissions [54], vehicle accidents, suicides and mur-
ders [36].
No one single intervention can totally reduce the con-
siderable burden of disease from smoking. A multi-faceted
approach is required, combining legislation, counter-
advertising, taxation, prevention and cessation interven-
tions [55].
Fortunately, many potential interventions to reduce
the human and monetary burden from smoking have
been identified and prioritized according to their cost-
utility ratios in Israel. Many very cost-effective interven-
tions have been identified in addition to interventions
that are cost-saving (ie: where savings in treatment costs
exceed the intervention costs). These include imposition
of a higher tax on tobacco, Clonidine, Nortiptyline, vare-
nicline (2 mg/day), Quitline Counseling and a combin-
ation of Medication and Quitline Counseling. Many
interventions were found to be very cost-effective (hav-
ing a cost per quality adjusted life year (QALY) less than
GNP per capita):- Nicotine lozenges, Varenicline (1 mg/
day), Nicotine patches with and without Nortipyline or
Burropion, Buropropin, Nicotine Gum, Group counseling,
Nicotine nasal spray, Individual Counseling, Nicotine in-
haler [5]. Other potential interventions, not yet evaluated
using cost-effectiveness analysis in Israel include novel
cheap modes such as mobile phone text-messaging as well
as pack warnings, ‘plain’ packaging and smoke-free space
regulations.
Unfortunately, Israel lags behind many developed na-
tions in that it does not use cost-utility analyses to
prioritize the adoption of new health technologies. There
may be several reasons for this inadequacy. One reason
may be insufficient appreciation within the Ministry of
Health of the importance of cost-utility analysis and of
recent advances in health economics which facilitate the
integration of epidemiological and economic data. An-
other reason may be that Israel tends to be an early
adopter of new technologies, with many new technolo-
gies being considered for inclusion in the benefits pack-
age well before all the data needed for cost utility
analyses are available. However, early adoption of suit-
able technologies can be still further catalyzed if a-priori
cost-utility analyses are carried out during the period be-
tween the conclusion of clinical trials and when manu-
facturers begin marketing the new technology.
Yet another reason for not using cost utility analyses
may be a desire to ensure that the members of the bene-
fits package committee (i.e. the committee that deter-
mines new entries into the basket of services) will have
enough degrees of freedom to take into account consid-
erations that are not captured in cost-utility analyses,
such as uniquely Israeli valuesa. However, there is nocontradiction between preserving some degrees of free-
dom for policymakers and providing them with sophis-
ticated cost-utility analyses as key inputs into the
decision-making process.
Accordingly, it behooves Israel to find ways to better in-
corporate cost-utility analyses into its prioritization pro-
cesses, both with regarding to smoking interventions, and
more generally. This could be done either by expanding the
role of health economics within the Ministry of Health, or
by establishing an institution akin to NICE, or by relying
more heavily on non-governmental experts and research
institutions.
We would also note that, in areas other than health care,
Israel has established funded bodies like the “authority for
the war against road accidents” and the “authority for the
war against drugs”. The considerable mortality burden
(around twenty times higher than that caused by traffic re-
lated mortality) attributable to smoking in this paper cries
out for the establishment of a “national authority” to co-
ordinate to identify and implement a multi-faceted inter-
vention strategy to decrease the considerable burden from
smoking in Israel.
Conclusion
Smoking causes a considerable burden in Israel, both in
terms of the expected 7,847 lives lost and the financial
costs of around 3,587 million NIS ($1,030 million or
0.41% of GNP). Many cost-effective and cost-saving in-
terventions exist that can reduce this huge burden on
society.
Endnote
aOne such uniquely-Israeli value is the high priority
given to fertility treatments. At the same time it should be
kept in mind that in the case of most major illnesses –
such as lung cancer, myocardial infarction, osteoporosis,
stroke or diabetes – we are unaware of any uniquely Israeli
values to be considered.
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